Diligence memo · auto-generated · as of July 2, 2026
Genvax Technologies, Inc.
Genvax Technologies, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Genvax Technologies, Inc. operates in Software / Tech, based in AMES.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Genvax Technologies, Inc. has raised $9.8M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $6.4M on 2022-06-02.
Most recent recorded round closed around 2024-06-07.
Valuation (modeled)modeled
Provath models Genvax Technologies, Inc. at approximately $19M (range $4.5M–$42M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.38× the median modeled value of Series A Software / Tech companies in 2022–2024 (413 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 24 months.
Last raise 2.1 yr ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round was 1.9× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 67% of Software / Tech peers (3920 compared).
Modeled value ranks above 38% of those peers.
Closest niche peers: Solidblock Holdings LLC Detox Digital Series, inFeedo Tech Inc., Red Leader Technologies, Inc., Mocha Technologies Inc., Isometric Technologies Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.